According to a recent LinkedIn post from Tubulis, clinical investigator Prof. Dr. Toon Van Gorp is expected to deliver a rapid oral presentation on Phase I/IIa data for lead candidate TUB-040 at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago in late May to early June 2026. The presentation is described as part of the Gynecologic Cancer session and will focus on maturing data from the ongoing dose escalation portion of the platinum-resistant ovarian cancer cohort.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post indicates that these data build on previously reported clinical activity and safety presented at ESMO 2025, suggesting a continued development trajectory for TUB-040 in a difficult-to-treat ovarian cancer population. For investors, the visibility at ASCO, combined with follow-up to earlier signals of activity, could represent a key catalyst for reassessing the asset’s risk profile and potential future value within Tubulis’ pipeline.
Tubulis’ LinkedIn post also highlights that TUB-040 is a next-generation NaPi2b-targeting antibody-drug conjugate developed using the company’s proprietary Tubutecan linker platform. The description emphasizes design features such as high stability, optimized targeting, and a high drug-to-antibody ratio (DAR8), which, if supported by forthcoming clinical data, may enhance the therapy’s competitive positioning in the ADC field and strengthen Tubulis’ technological differentiation in oncology partnerships and financing discussions.